Stay updated on DONATE Study: Dapagliflozin Safety in T2DM Clinical Trial
Sign up to get notified when there's something new on the DONATE Study: Dapagliflozin Safety in T2DM Clinical Trial page.

Latest updates to the DONATE Study: Dapagliflozin Safety in T2DM Clinical Trial page
- ChecktodayChange DetectedThe ClinicalTrials.gov platform revision advanced from v3.8.0 to v3.8.1, while the study record content remains unchanged.SummaryDifference0.0%

- Check7 days agoChange DetectedA MedlinePlus Genetics link about type 2 diabetes was added among the study’s related health resources.SummaryDifference0.1%

- Check14 days agoChange DetectedThe clinical-trial record for DONATE is now displayed, describing a completed observational study of dapagliflozin safety in people with type 2 diabetes in China, along with its eligibility criteria, locations, outcomes, and data-sharing details.SummaryDifference70%

- Check21 days agoChange DetectedThe footer’s displayed ClinicalTrials.gov revision changes from v3.7.2 to v3.8.0, while the page continues to show a 403 Forbidden error.SummaryDifference0.2%

- Check28 days agoChange DetectedA site-wide NIH notice announces updates and a transition from the term “Artificial Intelligence” to “Super Intelligence.” It appears above the page’s 403 error response.SummaryDifference1%

- Check35 days agoChange DetectedThe footer’s site revision identifier changed from v3.7.1 to v3.7.2.SummaryDifference0.2%

Stay in the know with updates to DONATE Study: Dapagliflozin Safety in T2DM Clinical Trial
Enter your email address, and we'll notify you when there's something new on the DONATE Study: Dapagliflozin Safety in T2DM Clinical Trial page.